Atuzaginstat (COR388), Cortexyme’s investigational oral therapy, effectively suppressed the activity of its target — toxic enzymes called gingipains — and was associated with reductions in several disease biomarkers in people with mild-to-moderate Alzheimer’s, according to updated data from the Phase 2/3 GAIN clinical trial. Similar to previously reported…
Aduhelm (aducanumab) continues to clear away amyloid plaques and tangled fibers made up of tau — two abnormal protein aggregates that build in the brain of those with Alzheimer’s disease — after nearly two and a half years of treatment, Biogen, which markets the treatment, reports. It also…
AEV103 (3,6’-dithiopomalidomide), a potentially immunomodulating medicine, was able to quell brain inflammation and slow cognitive decline in a mouse model of Alzheimer’s disease, a study has found. The medicine, developed originally at the National Institutes of Health (NIH) and now licensed to AevisBio, exerted its effects even…
The National Institute on Aging has awarded $2.85 million in funding to a research team from the University of Tennessee Health Science Center (UTHSC) to study the role of mitochondria  — cells’ powerhouses — in age-related diseases, such as Alzheimer’s. The five-year funding will support a project called…
Seelos Therapeutics is gearing up for a pilot study, in Australia, testing SLS-005 (trehalose) — its investigational therapy for people with Alzheimer’s disease — after receiving an acknowledgment letter from the country’s regulatory body for clinical trials. The letter, from the Australian Government Department of Health Therapeutic Goods…
Eisai has started submitting data to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in support of an application for approval of its investigational lecanemab (BAN2401) to treat early Alzheimer’s disease. This submission followed the company’s prior assessment consultation with the PMDA, given in advance of an approval application and intended…
Roche is launching a Phase 3 clinical trial to evaluate the ability of its investigational antibody therapy, gantenerumab, to slow Alzheimer’s progression in people with early signs of the disease, the company announced. Called SKYLINE (NCT05256134), the trial is now recruiting 1,200 cognitively unimpaired participants between…
LX1001, a one-time gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, raised levels of the protective APOE2 protein in the cerebrospinal fluid (CSF), early data from an ongoing Phase 1/2 trial shows. Findings in a first patient group treated at low dose also showed the gene therapy reduced the…
A clinical trial application for varoglutamstat, or PQ912, an investigational therapy for Alzheimer’s disease, was approved in China, its developers, Vivoryon Therapeutics and Simcere Pharmaceutical Group, announced. “We are proud to have obtained [China’s Center for Drug Evaluation] CDE approval of our Clinical Trial Application of varoglutamstat…
A biomarker blood test called AlzoSure Predict that can help to identify people with mild cognitive impairment who are likely progress to Alzheimer’s disease — years before symptoms are evident — has been approved for use in the European Union (EU) and the U.K., its marketer, Diadem, announced. “This…
Get regular updates to your inbox.